|
| Exchange Received Time 21/03/2017 08:56:06 Exchange Disseminated Time 21/03/2017 08:56:07 Time Taken 00:00:01 | | Further to our earlier communication to Stock Exchanges, we wish to state that US-FDA has issued an Import Alert 66-40 on 20th March 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. The Agency has exempted the following products from the Import Alert: 1. Levetiracetam 2. Gabapentin 3. Lamotrigine 4. Capecitabine 5. Naproxen sodium 6. Raltegravir potassium 7. Atovaquone 8. Chloropurine 9. BOC core succinate 10. 2,4-wing active ester Divi's Laboratories, along with third party consultants, is currently working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements. This is for your information and records. |
|
|